A detailed history of Mackenzie Financial Corp transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Mackenzie Financial Corp holds 13,140 shares of AKBA stock, worth $24,966. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,140
Previous 29,658 55.69%
Holding current value
$24,966
Previous $30,000 43.33%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.94 - $1.55 $15,526 - $25,602
-16,518 Reduced 55.69%
13,140 $17,000
Q2 2024

Aug 14, 2024

BUY
$0.86 - $1.63 $4,230 - $8,017
4,919 Added 19.88%
29,658 $30,000
Q1 2024

May 10, 2024

BUY
$1.27 - $2.24 $2,006 - $3,539
1,580 Added 6.82%
24,739 $45,000
Q4 2023

Jan 30, 2024

BUY
$0.8 - $1.28 $5,064 - $8,102
6,330 Added 37.61%
23,159 $28,000
Q3 2023

Oct 25, 2023

SELL
$0.87 - $1.84 $9,021 - $19,080
-10,370 Reduced 38.13%
16,829 $19,000
Q2 2023

Aug 03, 2023

SELL
$0.51 - $1.43 $7,250 - $20,328
-14,216 Reduced 34.33%
27,199 $25,000
Q1 2023

Apr 24, 2023

SELL
$0.56 - $1.15 $14,962 - $30,725
-26,718 Reduced 39.21%
41,415 $23,000
Q3 2022

Oct 07, 2022

BUY
$0.3 - $0.46 $7,602 - $11,656
25,341 Added 59.22%
68,133 $22,000
Q2 2022

Aug 10, 2022

BUY
$0.32 - $0.67 $6,697 - $14,022
20,929 Added 95.73%
42,792 $15,000
Q1 2022

May 13, 2022

BUY
$0.72 - $2.93 $419 - $1,708
583 Added 2.74%
21,863 $16,000
Q4 2021

Feb 14, 2022

BUY
$2.26 - $3.34 $48,092 - $71,075
21,280 New
21,280 $48,000
Q4 2020

Feb 10, 2021

SELL
$2.22 - $3.78 $46,176 - $78,624
-20,800 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$2.39 - $13.08 $80,146 - $438,624
-33,534 Reduced 61.72%
20,800 $52,000
Q2 2020

Aug 13, 2020

SELL
$6.67 - $13.58 $315,410 - $642,171
-47,288 Reduced 46.53%
54,334 $737,000
Q1 2020

May 14, 2020

BUY
$4.1 - $10.24 $267,328 - $667,668
65,202 Added 179.03%
101,622 $770,000
Q4 2019

Feb 13, 2020

BUY
$3.16 - $6.73 $115,087 - $245,106
36,420 New
36,420 $230,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $349M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Mackenzie Financial Corp Portfolio

Follow Mackenzie Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mackenzie Financial Corp with notifications on news.